Physician

Ahmed Al-Hazzouri, M.D.

According to 2025 Medicare claims, Ahmed Al-Hazzouri, M.D. (NPI: 1841482270) practices medical oncology in the Orlando-Kissimmee-Sanford, FL market, with the plurality of this provider's patient population coming from Lake, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32778-5270.

Al-Hazzouri's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,639 traditional Medicare patients, billed 437,342 HCPCS/CPT codes, and received $7,354,143 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,812 prescription claims across 664 beneficiaries totaling $12,652,982 in drug costs, led by Revlimid (Lenalidomide). DME data shows 82 claims. Open Payments data shows 80 records totaling $4,561. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $3,252,341 to $12,652,982. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $10,268 to $921.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,542	415,961	$4,764,240
2016	1,662	566,168	$6,039,369
2017	1,719	679,302	$7,136,615
2018	1,685	655,288	$7,703,992
2019	1,650	549,587	$7,087,487
2020	1,487	460,497	$6,777,731
2021	1,565	498,618	$7,877,546
2022	1,548	511,992	$8,380,329
2023	1,486	458,840	$7,190,069
2024	1,639	437,342	$7,354,143

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	368	2,544	$3,252,341
2016	418	2,924	$4,462,039
2017	474	2,845	$4,843,460
2018	493	2,939	$5,367,562
2019	527	2,939	$6,305,765
2020	502	2,877	$5,477,138
2021	544	3,224	$6,746,633
2022	565	3,250	$8,114,612
2023	611	3,466	$9,910,602
2024	664	3,812	$12,652,982

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	50	230	$48,004
2016	N/R	244	$54,273
2017	N/R	121	$14,953
2018	N/R	53	$5,653
2019	25	95	$7,494
2020	36	119	$6,360
2021	N/R	32	$2,324
2022	N/R	92	$2,859
2023	N/R	80	$7,500
2024	N/R	82	$1,759

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	582	1,495	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	665	980	$65
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	662	1,041	$13
36415	Insertion of needle into vein for collection of blood sample	1,121	3,213	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	1,062	3,415	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	171	4,753	$2,839,357
Ayvakit	Avapritinib	11	330	$1,217,857
Imbruvica	Ibrutinib	83	2,358	$1,198,952
Qinlock	Ripretinib	11	330	$878,636
Xtandi	Enzalutamide	63	1,890	$750,173

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	33	$895
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	13	$450
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	36	$414

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	80	$4,561	BeiGene USA, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ahmed Al-Hazzouri, M.D.?

Tedicare shows public-source Medicare data for Ahmed Al-Hazzouri, M.D. (NPI 1841482270), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ahmed Al-Hazzouri, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ahmed Al-Hazzouri, M.D.?

Ahmed Al-Hazzouri, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Ahmed Al-Hazzouri, M.D. have Open Payments data?

Ahmed Al-Hazzouri, M.D. has 80 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.